GlassScriptPhysician profile
Eugene M Pascarella
NPI 1821100975
$2,896.97
in general payments reported to CMS, 2019-2025
15 companies · $72.89 in 2025
The $72.89 reported for 2025 was less than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2020: $177 · 2021: $1,440 · 2022: $716 · 2023: $223 · 2024: $37.94 · 2025: $72.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $334.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Reel Surgical, INC. | $1,200.00 | 2021 | |
| Treace Medical Concepts, INC. | $508.85 | 2020-2022 | |
| Sanara Medtech INC. | $361.80 | 2022-2023 | Celleraterx |
| Smith+Nephew, INC. | $225.02 | 2019-2025 | Stravix Pl, Collagenase Santyl, Grafix Pl |
| Trilliant Surgical LLC. | $206.62 | 2019 | |
| Ossio INC | $145.08 | 2022 | |
| Anika Therapeutics, INC. | $78.96 | 2022 | |
| Kerecis Limited | $29.52 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Triad Life Sciences INC. | $27.80 | 2022 | |
| Grt US Holding, INC. | $24.40 | 2022 | |
| Organogenesis INC. | $21.86 | 2021 | |
| Abbott Laboratories | $19.61 | 2024 | Proclaim |
| Nevro Corp. | $18.33 | 2024 | Senza |
| Zimmer Biomet Holdings, INC. | $17.12 | 2021 | |
| Integra Lifesciences Corporation | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Pascarella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.